Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 20/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 20/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 20/20 | 0.51 |
| ▸ | KDR | P35968 | 15/20 | 0.51 |
| ▸ | VEGFA | P15692 | 4/20 | 0.50 |
| ▸ | FLT1 | P17948 | 4/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901401 | 0.92 | FGFR1 (0.60) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309677 | 0.90 | FGFR1 (0.49) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309731 | 0.86 | FGFR1 (0.52) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309648 | 0.84 | FGFR1 (0.49) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14901436 | 0.83 | FGFR3 (0.64) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309872 | 0.82 | FGFR1 (0.62) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL14901343 | 0.82 | FGFR1 (0.59) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309646 | 0.82 | FGFR1 (0.47) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309831 | 0.81 | FGFR3 (0.67) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20309607 | 0.81 | FGFR3 (0.62) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |